Gonorrhea Treatment: Current CDC-Recommended Regimen

Uncomplicated Gonorrhea: First-Line Therapy (CDC 2021 Guidelines)

Ceftriaxone 500 mg IM single dose (for persons <150 kg; 1 g IM if ≥150 kg).

Key Updates from Prior Guidelines

  • Dose increased from 250 mg → 500 mg due to rising MICs (minimum inhibitory concentrations).
  • Azithromycin 1 g oral no longer routinely recommended (rising macrolide resistance, no added benefit for uncomplicated GC).
  • Doxycycline 100 mg BID × 7 days added if chlamydia not ruled out (co-treatment).

Alternative Regimens (If Ceftriaxone Unavailable/Allergy)

  • Gentamicin 240 mg IM single dose PLUS Azithromycin 2 g oral single dose
  • Cefixime 800 mg oral single dose (less effective for pharyngeal infection)

Special Situations

Essential Follow-Up

  • Test-of-cure (NAAT) at 7–14 days for pharyngeal infection; otherwise not routine if treated with ceftriaxone.
  • Retest at 3 months (high reinfection rate).
  • Partner notification & treatment (EPT where legal).
  • HIV/syphilis testing at diagnosis.

Antimicrobial Resistance Threat

Neisseria gonorrhoeae has developed resistance to every antibiotic class used. Ceftriaxone is the last reliable monotherapy. Surveillance (GISP) monitors MIC trends. Novel agents (zoltavac, gepotidacin) in trials.

Takeaway: Single 500 mg IM ceftriaxone is the standard. Get tested, treated, and retested. Condoms prevent reinfection.

Gonorrhea - Related Articles

Health Sciences © https://www.222health.com

ScenarioManagement
Pharyngeal gonorrheaCeftriaxone 500/1000 mg IM only (cefixime unreliable)
PregnancyCeftriaxone 500 mg IM (safe); test-of-cure at 3–4 weeks
Cephalosporin allergy (anaphylaxis)Gentamicin 240 mg IM + Azithromycin 2 g oral; consult specialist
Disseminated GC (arthritis-dermatitis)Ceftriaxone 1 g IV/IM q24h × 7 days; switch to oral after 24–48 hrs improvement